Trial reportHaematologica2017
Prolonged
Trial report in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Treatment Study Protocol of the ALLTogether Consortium for Infants, Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL): a Pilot Study
ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
Who cites it
14 citing papers in PubMed, 31 citations in OpenAlex.
- JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Physicochemical quality assessment of four asparaginases.PloS one · 2025Article
- Results of the prospective EORTC Children Leukemia Group study 58081 in precursor B- and T-cell acute lymphoblastic leukemia.HemaSphere · 2024Article
- Refining risk prediction in pediatric acute lymphoblastic leukemia through DNA methylation profiling.Clinical epigenetics · 2024Article
- The frequency ofFrontiers in oncology · 2024Article
- Article
- Are clinical pharmacology studies still needed in childhood acute lymphoblastic leukemia?Haematologica · 2022Article
- Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy.Haematologica · 2022Article
- Favorable Trisomies andJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Article
- Article
- A pilot study of procoagulant platelet extracellular vesicles and P-selectin increase during induction treatment in acute lymphoblastic leukaemia paediatric patients: two new biomarkers of thrombogenic risk?Journal of thrombosis and thrombolysis · 2021Article
- Pharmacogenomics and ALL treatment: How to optimize therapy.Seminars in hematology · 2020Review
- Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia.The Lancet. Oncology · 2019Review
- Asparaginase: an old drug with new questions.Hematology, transfusion and cell therapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 20 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asparaginase is an essential component of combination chemotherapy for childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma. The value of asparaginase was further addressed in a group of non-very high-risk patients by comparing prolonged (long-asparaginase)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.